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Introduction {#sec1}
============

The transcriptional coactivator YAP1 and its fly counterpart Yorkie drive tissue and organ growth in flies and mammals \[[@bib1]\]. Originally delineated in flies, the Hippo kinase phosphorylates the Lats/Warts kinase, which in turn restricts Yorkie activity by phosphorylating serine 168 (S168) \[[@bib2]\]. The core of the mammalian Hippo pathway is composed of MST1/2 and LATS1/2 kinases, the mammalian Hippo and Lats/Warts homologs. MST1/2 phosphorylate LATS1/2, which in turn phosphorylate YAP1 on serine 127 (S127), the mammalian equivalent of Yorkie S168 \[[@bib3]\], resulting in cytoplasmic retention and decreased transcription of YAP1 target genes \[[@bib4]\]. Overexpression studies of YAP1 in transgenic mice revealed YAP1 as a player in cellular transformation in vivo \[[@bib5; @bib6]\]. Subsequent mouse models demonstrated that MST1/2 kinases are required to suppress the oncogenic potential of YAP1 in the liver and the intestinal epithelium \[[@bib7; @bib8; @bib9; @bib10]\], yet none of these models provided strong evidence for LATS1/2 as direct YAP1-S127 kinases. One study suggested that in the liver, MST1/2 activate a kinase distinct from LATS1/2 to phosphorylate YAP1 on S127 \[[@bib9]\]. Another study did not address how deregulation of MST1/2 impacts on S127 phosphorylation in the liver \[[@bib8]\]. In the intestinal epithelium, ablation of MST1/2 kinase activity results in YAP1-dependent crypt hyperplasia \[[@bib10; @bib11]\]. However, the YAP1-S127 kinase functioning downstream of MST1/2 was not addressed in the intestinal epithelium \[[@bib10; @bib11]\].

Mammalian NDR kinases are the closest homologs of LATS1/2 \[[@bib12]\]. The mammalian genome encodes two highly similar isoforms, NDR1 and NDR2, which are located at distinct genomic loci \[[@bib13]\]. Functionally, NDR kinases have been reported to regulate centrosome duplication \[[@bib14; @bib15]\], apoptosis \[[@bib16; @bib17]\], proliferation \[[@bib18]\], and chromosome alignment \[[@bib19; @bib20]\] in tissue-cultured cells. We previously published that loss of *Ndr1* predisposes mice to T cell lymphoma development \[[@bib16]\], suggesting a tumor-suppressive function of mammalian NDR kinases. The same study showed that NDR2 protein, but not mRNA, is upregulated upon genetic *Ndr1* deletion, suggesting that compensatory effects between the two mammalian NDR isoforms prevent the discovery of additional physiological functions of NDR kinases.

In summary, in the intestinal epithelium, direct physiological regulators of YAP1 by phosphorylation are currently unknown. The present study shows that mammalian NDR kinases phosphorylate YAP1 on S127 in vitro in tissue-cultured cells and in vivo in the intestinal epithelium. Phosphorylation of YAP1 at S127 by NDR mediates sequestration of YAP1 in the cytoplasm, restricts the transcriptional coactivator function of YAP1, and suppresses proliferation of human colon cancer cells.

Results {#sec2}
=======

Mammalian NDR Kinases Restrain Proliferation and Hyperplastic Growth in the Intestinal Epithelium {#sec2.1}
-------------------------------------------------------------------------------------------------

NDR1 protects against T cell lymphoma development and is highly expressed in organs of the immune system. Conversely, NDR2 is most abundant in the gastrointestinal tract \[[@bib13; @bib16]\]. Therefore, we hypothesized that NDR2 might function as a tumor suppressor in the colonic epithelium. To test this hypothesis and avoid compensation by NDR1, we ablated NDR2 specifically in the intestinal epithelium of *Ndr1* null mice ([Figure S1](#app2){ref-type="sec"}A available online) \[[@bib16; @bib21]\]. Specific ablation of NDR2 in the intestinal epithelium, denoted *N2* cKO (conditional single knockout), was confirmed by immunohistochemistry with an NDR2-specific antibody ([Figure S1](#app2){ref-type="sec"}B). *Ndr1* null mice lacking NDR2 in the intestinal epithelium, denoted *N1/2* cDKO (conditional double knockout), were born in the expected Mendelian ratios, developed no obvious morphological abnormalities, and did not display spontaneous tumor formation in the colon (monitored for up to 24 months; data not shown). However, the intestinal epithelium of *N1/2* cDKO adult mice (aged 16--20 weeks) displayed hyperplastic areas, which were absent in *Ndr1* and *Ndr2* single KO and wild-type controls ([Figures 1](#fig1){ref-type="fig"}A and 1B; data not shown). Subsequent histological analyses revealed that the secretory lineage and absorptive enterocytes in *N1/2* cDKO mice were indistinguishable from control animals ([Figure S1](#app2){ref-type="sec"}C). Taken together, these findings suggest that mammalian NDR prevents hyperplastic growth in the intestinal epithelium but is dispensable for differentiation of the secretory lineage and absorptive enterocytes.

Further histological analyses of *N1/2* cDKO intestines revealed the presence of aberrant crypts, characterized by enlarged nuclei, a thickened epithelial cell layer, and loss of apical-basal polarity ([Figure S1](#app2){ref-type="sec"}D). These abnormal crypts resembled so-called β-catenin-accumulated crypts (BCACs), which have been proposed as biomarkers for colon carcinogenesis in rodents and humans \[[@bib22]\]. Indeed, we detected increased β-catenin levels in aberrant crypts in *N2* cKO and *N1/2* cDKO but not in wild-type, wild-type-Vil-Cre, or *N1* KO mice ([Figure S1](#app2){ref-type="sec"}E), suggesting that NDR2 ablation can result in BCAC formation.

To characterize the hyperplastic phenotype of *N1/2* cDKO intestines further, we determined the proliferation index of *N1/2* null and control epithelia ([Figures 1](#fig1){ref-type="fig"}C and 1D; [Figure S1](#app2){ref-type="sec"}F). The entire proliferative zone of *N1/2* null colonic epithelia in both normal and hyperplastic areas was extended 2-fold compared to wild-type and *Ndr1* single KO mice. *N2* cKO colonic epithelia displayed an intermediate increase in proliferation, indicating that NDR1 compensates only partially for NDR2 loss in this compartment. To further analyze the proliferative behavior of NDR-deficient intestinal epithelial cells (IECs), we performed colony formation assays as described \[[@bib23]\] revealing that primary IECs isolated from *N1/2* cDKO mice formed similar numbers of colonies as controls (data not shown). However, *N1/2* null colonies grew significantly larger than wild-type colonies ([Figure S1](#app2){ref-type="sec"}F). In summary, our data indicate that mammalian NDR kinases restrict proliferation of intestinal epithelial cells in vivo.

NDR Protects Mice against Azoxymethane/Dextran Sodium Sulfate-Induced Colon Carcinogenesis {#sec2.2}
------------------------------------------------------------------------------------------

Although *N1/2* cDKO mice developed intestinal hyperplasia and BCACs ([Figure 1](#fig1){ref-type="fig"}; [Figures S1](#app2){ref-type="sec"}C and S1D), we did not observe progression to adenocarcinoma in the genetic background analyzed (mixed C57B/L6-Ola129). Spontaneous colon cancer development in rodents is rare \[[@bib24]\]. Therefore, we assessed whether NDR protects mice against chemically induced colon carcinogenesis \[[@bib25]\]. *Ndr* KO and control mice were treated with the colonotropic mutagen azoxymethane (AOM) and the inflammatory agent dextran sodium sulfate (DSS) as depicted in [Figure 2](#fig2){ref-type="fig"}A. Regardless of NDR status, all but one control mouse developed colonic nodules, indicating that the treatment reproducibly induced colon carcinogenesis. A representative pair of AOM/DSS-treated *N1/2* cDKO versus control colon is shown in [Figure 2](#fig2){ref-type="fig"}B. Based on histopathological analysis, all nodules analyzed were diagnosed as adenocarcinoma ([Figure 2](#fig2){ref-type="fig"}C; [Figure S2](#app2){ref-type="sec"}). However, whereas control mice (WT Vil-Cre) developed 2 or 3 nodules throughout their colon, *N1/2* cDKO mice developed 16 nodules on average ([Figure 2](#fig2){ref-type="fig"}D; [Table S1](#app2){ref-type="sec"}). Although nodule lumping precluded rigorous quantification of nodule size in *N1/2* cDKO epithelia, isolated nodules appeared to be of similar size in KO and control animals at dissection (data not shown). Ablation of *Ndr2* alone increased the average nodule number per mouse to six, whereas *Ndr1* single KO had no effect on nodule numbers compared to controls ([Figure 2](#fig2){ref-type="fig"}D). Intriguingly, these observations fully parallel our in vivo proliferation measurements ([Figures 1](#fig1){ref-type="fig"}C and 1D), namely that loss of NDR2 alone, but not loss of NDR1, increases proliferation in the colonic epithelium, which is further increased in *N1/2* cDKO mice ([Figure 1](#fig1){ref-type="fig"}D). Taken together, our data indicate that mammalian NDR kinases suppress tumor initiation in the intestinal epithelium.

NDR2 Protein Is Progressively Lost during AOM/DSS-Induced Colon Carcinogenesis {#sec2.3}
------------------------------------------------------------------------------

Having shown that NDR partially protects against AOM/DSS-induced carcinogenesis in *Ndr* KO mice, we next took the reverse approach and applied the AOM/DSS model to wild-type mice to assess whether NDR2 expression was lost during colon carcinogenesis. We subjected wild-type mice to the AOM/DSS protocol described in [Figure 2](#fig2){ref-type="fig"}A. Changes in the colonic epithelium were monitored at the time points indicated: prior to the AOM injection (day 0), day 7, day 21 (upon completion of DSS administration), day 42, and at termination (day 64). AOM treatment induces changes in β-catenin localization \[[@bib26; @bib27]\], a hallmark of human colorectal cancer \[[@bib28]\]. Therefore, we assessed β-catenin expression together with hematoxylin and eosin (H&E) and Ki-67 staining to evaluate molecular, morphological, and proliferative changes. In parallel, we monitored NDR2 protein expression using our isoform-specific antibody ([Figure S1](#app2){ref-type="sec"}B). As expected, naive control mice displayed an intact colonic epithelium and cytoplasmic β-catenin localization and proliferating cells were confined to the crypt base ([Figure 3](#fig3){ref-type="fig"}A, I, III, and IV). NDR2 expression was detected throughout the entire epithelium ([Figure 3](#fig3){ref-type="fig"}A, II). One week after AOM injection ([Figure 3](#fig3){ref-type="fig"}B), tissue architecture, β-catenin localization, and NDR2 levels remained unchanged whereas the Ki-67-positive compartment appeared slightly extended upward ([Figure 3](#fig3){ref-type="fig"}B, IV). After DSS treatment (day 21), the colonic epithelium was destroyed and crypt regeneration was apparent ([Figure 3](#fig3){ref-type="fig"}C). Some crypts showed aberrant morphology ([Figure 3](#fig3){ref-type="fig"}C, I). β-catenin signals were increased and occasionally nuclear ([Figure 3](#fig3){ref-type="fig"}C, III). Aberrant crypts displayed strong Ki-67 expression, indicating elevated proliferation rates ([Figure 3](#fig3){ref-type="fig"}C, III and IV). NDR2 levels appeared generally decreased, in line with our hypothesis that NDR restricts proliferation in the intestinal epithelium ([Figure 3](#fig3){ref-type="fig"}C, II). On day 42, aberrant crypts had formed in the regenerated colonic epithelium ([Figure 3](#fig3){ref-type="fig"}D, I). We did not detect adenoma or adenocarcinoma at this time point. β-catenin and Ki-67 signals were comparable to the previous time point (day 21) ([Figure 3](#fig3){ref-type="fig"}D, III and IV). However, NDR2 levels in aberrant crypts were diminished compared to adjacent normal crypts ([Figure 3](#fig3){ref-type="fig"}D, II). Nine weeks after AOM injection (day 64), adenocarcinomas had formed and β-catenin signals were strongly increased, displaying nuclear localization ([Figure 3](#fig3){ref-type="fig"}E, I and III). The majority of cells within the nodules were Ki-67 positive ([Figure 3](#fig3){ref-type="fig"}E, IV). Whereas stroma cells retained residual NDR2 levels, NDR2 protein was absent in the majority of adenocarcinoma nodules ([Figure 3](#fig3){ref-type="fig"}E, II). Importantly, NDR2 protein levels in adjacent normal crypts were comparable to those detected prior to AOM treatment (compare [Figure 3](#fig3){ref-type="fig"}A, II and [Figure 3](#fig3){ref-type="fig"}E, II). In summary, NDR2 protein is progressively lost during AOM-induced colon carcinogenesis and absent in adenocarcinoma, supporting our hypothesis that NDR2 functions as a tumor suppressor protein in the colon.

Levels of the YAP1 Oncoprotein Are Increased upon NDR Ablation {#sec2.4}
--------------------------------------------------------------

The Hippo-YAP1 pathway regulates organ growth \[[@bib29; @bib30]\]. Current evidence suggests that the Hippo core kinase cassette---MST1/2 and LATS1/2 in mammals---inactivates the transcriptional coactivator YAP1 by LATS1/2-mediated phosphorylation. Upon phosphorylation at serine 127 by LATS kinases \[[@bib4; @bib6]\], YAP1 can be retained in the cytoplasm. Phosphorylation of serine 381 (S381) by LATS can trigger YAP1 degradation \[[@bib31]\]. In the absence of Hippo pathway activity, YAP1 can enter the nucleus and drive proproliferative gene expression. Although YAP1 is dispensable for normal intestinal development and homeostasis \[[@bib11]\], its oncogenic potential is unleashed in the absence of Hippo pathway activity \[[@bib10; @bib11]\]. Importantly, whether LATS1/2 can directly regulate YAP1 in the intestinal epithelium remains to be addressed \[[@bib10]\]. NDR kinases are the closest homologs of LATS kinases \[[@bib12]\]. Hao et al. \[[@bib32]\] reported that human NDR can phosphorylate YAP1 in vitro. However, neither the phosphorylation site(s) nor the biological significance of this phosphorylation event was examined. Therefore, we hypothesized that NDR kinases might regulate YAP1 in the intestinal epithelium, which could explain why *N1/2* cDKO animals are more susceptible to chemically induced tumorigenesis. To examine this hypothesis, we asked whether loss of NDR deregulates YAP1 activity by altering YAP1 phosphorylation in the intestinal epithelium. Murine S112 is the equivalent of human S127 \[[@bib3]\]. Significantly, phospho-S112 levels were decreased whereas total YAP1 protein levels were increased in lysates of the intestinal epithelium derived from *N2* cKO and *N1/2* cDKO mice ([Figures 4](#fig4){ref-type="fig"}A and 4B). In contrast, phosphorylation of YAP1 at S382, the murine equivalent of human S381, was unaffected ([Figure 4](#fig4){ref-type="fig"}A). Importantly, LATS1 total protein levels and LATS activity as determined by phosphorylation status were unchanged. Total MST1 and phospho-MST1/2 (Thr183/180) levels, indicative of MST1/2 activity, also remained unchanged ([Figure 4](#fig4){ref-type="fig"}A). These findings demonstrate that the observed decrease of YAP1 phosphorylation was caused by the absence of NDR kinases and not altered MST-LATS signaling. Immunohistochemistry (IHC) staining of tissue sections confirmed the upregulation of YAP1 protein in the intestinal epithelium of *N1/2* cDKO and *N2* cKO mice and revealed that YAP1 is mainly nuclear both in KO and control animals ([Figure 4](#fig4){ref-type="fig"}C; [Figures S3](#app2){ref-type="sec"}A--S3D).

To define whether decreased YAP1 phosphorylation and elevated YAP1 protein levels upon loss of NDR translated into increased YAP1 activity in vivo, we employed two complementary approaches. YAP1 overexpression in the intestine correlates with downregulation of the tumor suppressor PTEN \[[@bib33]\], exerting its tumor-suppressive functions in part by decreasing Cyclin D1 levels \[[@bib34]\]. In agreement with increased YAP1 activity upon NDR loss, we found decreased PTEN and increased Cyclin D1 protein levels in *N1/2* null colons ([Figures 4](#fig4){ref-type="fig"}A and 4D; [Figures S3](#app2){ref-type="sec"}E--S3H). As a second approach, we assessed the expression of YAP1 target gene expression in the intestinal epithelium of *N1/2* cDKO mice by in situ hybridization (ISH). CTGF, an established transcriptional target of YAP1/TEAD \[[@bib35]\], was only detectable in the intestinal stroma (data not shown), a tissue where *Ndr2* is not deleted by the Villin-Cre transgene in our KO mice. Thus, we examined BDNF, another YAP1 target gene \[[@bib35]\], by ISH, revealing that *Bdnf* transcripts were more than 2-fold upregulated in *N1/2* cDKO mice compared to controls ([Figure 4](#fig4){ref-type="fig"}E; [Figures S3](#app2){ref-type="sec"}I and S3J), indicating that NDR restrains YAP1 target gene expression in vivo. Taken together, our data suggest that elevated YAP1 levels upon loss of NDR translate into increased YAP1 activity in vivo.

Next, to test the relevance of YAP1 regulation by NDR in the intestinal epithelium, we asked whether the observed hypersensitivity to chemical carcinogenesis of *N1/2* cDKO mice was functionally linked to YAP1 levels. To address this question, we concomitantly ablated *YAP1* in *N1/2* cDKO mice and subjected them to AOM-mediated colon carcinogenesis as outlined in [Figure 2](#fig2){ref-type="fig"}B. Significantly, removal of one *YAP1* allele was sufficient to reduce tumor formation in *N1/2* cDKO mice from 15 to 5 nodules on average (compare [Figures 2](#fig2){ref-type="fig"}D and [4](#fig4){ref-type="fig"}F). Therefore, NDR is functionally required to restrict the oncogenic potential of YAP1 in the intestinal epithelium.

NDR Functions as a YAP1 Kinase Phosphorylating YAP1 on Serine 127 {#sec2.5}
-----------------------------------------------------------------

Given the intriguing inverse correlation between NDR loss, decreased YAP1 phosphorylation, and increased YAP1 activity in the intestine ([Figure 4](#fig4){ref-type="fig"}), we investigated whether NDR impacts directly on YAP1 regulation. To address whether and where NDR phosphorylates YAP1 directly, we performed in vitro kinase assays with recombinant human YAP1 and NDR-PIF, a constitutively active form of NDR \[[@bib36]\]. Indeed, active, but not kinase-dead, NDR-PIF phosphorylated YAP1 as determined by autoradiography ([Figure 5](#fig5){ref-type="fig"}A, middle panel). Subsequent western blotting revealed that NDR phosphorylates YAP1 on S127 ([Figure 5](#fig5){ref-type="fig"}A, top panel), identifying for the first time a YAP1-S127 kinase distinct from LATS1/2. Next, we performed mass spectrometry to determine additional sites on YAP1 targeted by NDR, identifying three additional serines, namely S61, S109, and S164, to also be phosphorylated by NDR in vitro ([Table S2](#app2){ref-type="sec"}). Significantly, all four sites---S61/S109/S127/S164---are also phosphorylated by LATS \[[@bib4; @bib32]\], suggesting that LATS and NDR kinases can function as YAP1 kinases. Collectively, our kinase assays clearly establish NDR kinases as novel bona fide upstream kinases of YAP1 in vitro.

To investigate whether NDR kinases function as YAP1 kinases in mammalian cells, we overexpressed NDR in the colon cancer cell line SW480 and assessed S127 phosphorylation ([Figure 5](#fig5){ref-type="fig"}B). In line with our hypothesis that NDR regulates YAP1 by phosphorylation, we found that wild-type---but not inactive---NDR increased the ratio of S127 phosphorylation significantly ([Figure 5](#fig5){ref-type="fig"}B). Contrarily, S381 phosphorylation was unaffected ([Figure 5](#fig5){ref-type="fig"}B). Inducible overexpression of NDR in stably transfected SW480 cells (tet-on system) and transient transfection experiments in HCT116 cells yielded comparable results ([Figure 5](#fig5){ref-type="fig"}C; [Figure S4](#app2){ref-type="sec"}B), excluding the possibility that the observed effects are cell line specific. In summary, our data demonstrate that NDR kinases phosphorylate YAP1 directly on serine 127 in vitro and in tissue-cultured cells. Significantly, these findings fully support our initial observation of decreased S127 phosphorylation in *N1/2* cDKO animals in vivo ([Figure 4](#fig4){ref-type="fig"}A).

NDR Regulates the Localization and Transcriptional Activity of YAP1 {#sec2.6}
-------------------------------------------------------------------

Considering that phosphorylation of YAP1 at S127 can result in the inactivation of YAP1 by cytoplasmic retention \[[@bib4; @bib6]\] and that NDR phosphorylates YAP1 at S127 ([Figure 5](#fig5){ref-type="fig"}), we reasoned that NDR overexpression might reduce nuclear YAP1 levels and consequently YAP1 activity as a transcriptional coactivator. To test this hypothesis, we quantified endogenous YAP1 localization by immunofluorescence in our tetracycline (tet)-inducible colon cancer cell lines described above ([Figure 5](#fig5){ref-type="fig"}C). The ratio of nuclear versus cytoplasmic YAP1 was significantly reduced in cells overexpressing wild-type NDR compared to controls that overexpressed kinase-dead NDR ([Figure 6](#fig6){ref-type="fig"}A). Signals for total YAP1 levels were also reduced upon overexpression of active NDR ([Figure 6](#fig6){ref-type="fig"}A). The same was observed in a transient overexpression setting ([Figure S4](#app2){ref-type="sec"}A). Because the exclusion of YAP1 from the nucleus was dependent on NDR kinase activity ([Figure 6](#fig6){ref-type="fig"}A; [Figure S4](#app2){ref-type="sec"}A), these results suggest that this regulatory event is controlled by NDR-mediated YAP1 phosphorylation.

Nuclear YAP1 associates with TEAD transcription factors (TFs) to drive target gene expression \[[@bib1]\]. Therefore, we assessed whether NDR-mediated YAP1 phosphorylation interferes with endogenous YAP1 transcriptional activity. Making use of a published TEAD luciferase reporter assay \[[@bib37]\], we found that overexpression of wild-type NDR led to a 7-fold drop in reporter activity ([Figure 6](#fig6){ref-type="fig"}B). Conversely, overexpression of kinase-dead NDR resulted in a 2.7-fold increase, suggesting that catalytically inactive NDR acts in a dominant-negative manner as already reported in another setting \[[@bib15]\]. Collectively, these data indicate that NDR can suppress YAP1 activity in a kinase activity-dependent manner, resulting in cytoplasmic retention of YAP1 when NDR kinase is overexpressed.

Considering that YAP1 drives proliferation in colon cancer \[[@bib10; @bib38]\] and that NDR negatively regulates YAP1 levels and activity, we asked next whether NDR negatively affects YAP1-dependent proliferation of human colon cancer cells. In full agreement with a previous report \[[@bib10]\], knockdown of YAP1 in SW480 cells reduced proliferation ([Figures S4](#app2){ref-type="sec"}C and S4D), illustrating that proliferation of SW480 cells is YAP1 dependent. Significantly, we observed a similar effect upon tet-induced overexpression of wild-type NDR in SW480 cells ([Figure 6](#fig6){ref-type="fig"}C). Overexpression of kinase-dead NDR had no effect ([Figure 6](#fig6){ref-type="fig"}C), showing that proliferation was negatively affected in a manner dependent on NDR kinase activity. Moreover, overexpression of wild-type NDR significantly suppressed colony formation in contrast to controls ([Figure 6](#fig6){ref-type="fig"}D). Overexpression of kinase-dead NDR had no suppressive effect ([Figure 6](#fig6){ref-type="fig"}D). Collectively, these findings demonstrate the negative impact of NDR kinase activity on the proliferative capacity of colon cancer cells. This observation parallels our findings that NDR loss in vivo increases proliferation ([Figure 1](#fig1){ref-type="fig"}) and sensitizes mice to adenocarcinoma nodule formation upon exposure to AOM ([Figure 2](#fig2){ref-type="fig"}). Mechanistically, these findings demonstrate that forced expression of active NDR results in a redistribution of YAP1 protein to the cytoplasm and decreased transcriptional activity of YAP1. Functionally, our data indicate that active NDR restricts proliferation of colon cancer cells.

Finally, we turned to clinical colon cancer samples to address the relevance of our findings in human patients. Initially, we detected an inverse correlation of NDR2 and YAP1 protein expression in six out of ten adenocarcinoma samples. More specifically, YAP1 expression was elevated in the tumor and low in the adjacent normal crypts, whereas the opposite was true for NDR2 ([Figure 7](#fig7){ref-type="fig"}A). To increase the spectrum of our analysis, we assessed YAP1 and NDR2 protein levels in a tissue microarray with 325 independent human colon cancer samples. Examples of high and low NDR2 and YAP1 scores as determined by IHC are shown in [Figure 7](#fig7){ref-type="fig"}B. Significantly, the majority of human tumors with increased YAP1 levels expressed only low amounts of NDR2 whereas NDR2 expression in YAP1-low tumors was variable ([Figure 7](#fig7){ref-type="fig"}C; [Table S3](#app2){ref-type="sec"}), in line with our observation that, in mice, YAP1 levels in the intestinal epithelium are increased in the absence of NDR ([Figure 4](#fig4){ref-type="fig"}). Collectively, this analysis of clinical samples indicates that NDR2 kinase might also play a tumor-suppressive role in the human intestine.

Discussion {#sec3}
==========

In the present study, we identify mammalian NDR1/2 as novel YAP1 kinases in vitro and in vivo. Recombinant NDR phosphorylates YAP1 on S127 and other reported LATS sites. In tissue-cultured cells, NDR regulates YAP1 function and phosphorylation in a kinase activity-dependent manner. Loss of NDR in the murine intestinal epithelium results in decreased YAP1 phosphorylation, increased total YAP1 levels, and, consequently, elevated cotranscriptional activity of YAP1 in vivo. Most importantly, ablation of NDR in vivo deregulates YAP1 levels and activity without obviously altering MST1/2-LATS1/2 signaling, strongly suggesting that the observed deregulation of YAP1 is a direct effect of the absence of NDR kinases.

Mammalian NDR kinases are the closest homologs of LATS kinases \[[@bib12]\], the only established YAP1-S127 kinases so far. NDR and LATS kinases efficiently phosphorylate the same synthetic substrate peptide \[[@bib39; @bib40]\] and a peptide based on the sequence surrounding S127 on YAP1 \[[@bib32]\]. Moreover, NDR and LATS kinases appear to be regulated in a similar fashion \[[@bib3]\]. MST1/2 kinases can function as upstream kinases of LATS \[[@bib41]\] and NDR \[[@bib14; @bib17]\], and hMOB1 proteins act as coactivators for both NDR \[[@bib14; @bib17; @bib42; @bib43; @bib44]\] and LATS kinases \[[@bib39; @bib45; @bib46; @bib47]\]. Similar regulatory parallels have been observed in flies, namely that Hippo, the fly homolog of mammalian MST1/2, functions upstream of both Lats and Trc, the fly counterparts of NDR/LATS \[[@bib48]\]. Likewise, the coactivator Mats/dMOB1, the homolog of hMOB1, regulates Lats and Trc in flies \[[@bib49; @bib50]\]. Therefore, given that NDR and LATS kinases share similar regulatory mechanisms and substrate signatures \[[@bib3]\], our discovery of NDR as a novel S127 kinase fits perfectly into the context of previously published data. Furthermore, our findings, together with the published regulatory similarities, suggest that MST1/2-MOB1 signaling might use diverse routes to regulate YAP1 phosphorylation. Therefore, future studies of NDR/Trc signaling downstream of MST/Hippo and MOB1/Mats are warranted in yet-to-be-established animal models.

Mechanistically, NDR-mediated YAP1-S127 phosphorylation drives cytoplasmic sequestration of YAP1 and suppresses YAP1-driven reporter activity ([Figure 6](#fig6){ref-type="fig"}). These observations recapitulate the effects reported for LATS on YAP1 in tissue-cultured cells \[[@bib4]\]. Functionally and in full support of our finding that NDR negatively regulates YAP1 activity, NDR impairs proliferation and colony formation of YAP1-dependent colon cancer cells ([Figure 6](#fig6){ref-type="fig"}). Conversely, combined loss of murine NDR1/2 in the intestinal epithelium results in reduced YAP1 phosphorylation, whereas total YAP1 protein levels are increased ([Figure 4](#fig4){ref-type="fig"}). On a functional level in the intestine, YAP1 transcriptional coactivator activity is increased ([Figure 4](#fig4){ref-type="fig"}) and the proliferative zone of the epithelium is extended ([Figure 1](#fig1){ref-type="fig"}). Therefore, to our knowledge, the *Ndr* KO mice described in this study are the first animal model providing comprehensive in vivo evidence of a direct YAP1-S127 kinase. Follow-up studies are now needed to examine whether NDRs also function as S127 kinases in other organs such as the liver, whose tissue homeostasis is tightly regulated by YAP1 phosphorylation \[[@bib9]\].

Although numerous studies have investigated S127 phosphorylation and its impact on YAP1 regulation (reviewed in \[[@bib1; @bib30]\]), additional sites on YAP1 are phosphorylated by LATS, namely S61, S109, S164, and S381 \[[@bib4; @bib32]\]. Phosphorylation at S381 primes YAP1 for proteasome-mediated degradation \[[@bib31]\], whereas the function of the other phospho sites has remained enigmatic \[[@bib3]\]. We found that NDR targets S61, S109, and S164 ([Table S2](#app2){ref-type="sec"}) but did not observe S381 phosphorylation. In this context, the levels of phospho-S382, the murine equivalent of hYAP1 S381, are comparable in the intestinal epithelium of *N1/2* cDKO and control mice ([Figure 4](#fig4){ref-type="fig"}), and overexpression of active NDR does not increase S381 phosphorylation in tissue-cultured cells ([Figure 5](#fig5){ref-type="fig"}). Interestingly, total YAP1 protein levels are still increased in the absence of NDR ([Figure 4](#fig4){ref-type="fig"}) and decreased upon NDR overexpression ([Figure 5](#fig5){ref-type="fig"}), suggesting that alternative mechanisms to S381 phosphorylation must exist to regulate YAP1 protein levels in vivo. Whether these mechanisms are mediated by the other identified phosphorylation sites---S61, S109, or S164---or triggered by more indirect effects remains to be addressed with regard to NDR signaling.

Ablation of mammalian Hippo---*Mst1/2*---in the intestinal epithelium results in hyperproliferation through YAP1 upregulation \[[@bib10]\]. However, the direct physiological S127 kinase in this tissue was not defined experimentally \[[@bib10]\]. Mice with specific LATS1/2 deletion in the intestinal epithelium have not been reported thus far. Instead, we show that NDR1/2 loss in the intestinal epithelium leads to increased proliferation and the formation of hyperplastic foci ([Figure 1](#fig1){ref-type="fig"}). Therefore, we are tempted to speculate that MST1/2 kinases restrict proliferation in the intestinal epithelium at least in part via NDR kinase signaling. However, loss of NDR1/2 in the intestinal epithelium results in a substantially weaker YAP1-dependent phenotype than ablation of *Mst1/2* \[[@bib10]\] or *Sav1*, a scaffold protein of the MST1/2 kinase complex \[[@bib11]\]. This indicates that MST1/2 kinases presumably regulate additional downstream targets distinct from NDR that impact on YAP1 regulation in the intestinal epithelium. Clearly more work is required to test whether LATS or other yet-to-be-identified YAP1 kinases/regulators play a role in controlling YAP1 in the intestinal epithelium.

Already-reported mouse models provide strong evidence suggesting that loss of S127 phosphorylation mimicked by the introduction of an S127A YAP1 mutant or loss of the MST1/2 upstream kinases is sufficient to drive hyperproliferation, expansion of progenitor cell compartments, and tumorigenesis in the intestinal epithelium \[[@bib5; @bib10]\]. Although *N1/2* cDKO animals do not develop spontaneous tumors, they are exquisitely more sensitive to chemically induced colon carcinogenesis than wild-type controls ([Figure 2](#fig2){ref-type="fig"}). Significantly, this hypersensitivity is reduced by concomitant removal of one *Yap1* allele ([Figure 4](#fig4){ref-type="fig"}E), indicating that loss of NDR drives carcinogenesis through YAP1 in the intestinal epithelium. Importantly, we observe that only combined loss of both NDR1 and NDR2 gives rise to the full tumor phenotype ([Figure 2](#fig2){ref-type="fig"}) and hyperproliferation ([Figure 1](#fig1){ref-type="fig"}), supporting our earlier speculations \[[@bib16]\] that NDR2 can partially compensate for the absence of NDR1 in *Ndr1* KO mice. In further support of a tumor-suppressive function of NDR2 in the intestinal epithelium, we found that loss of NDR2 correlates with tumor onset in wild-type mice with chemically induced carcinogenesis ([Figure 3](#fig3){ref-type="fig"}). Of equal importance, the majority of patient samples on a colon cancer tissue microarray displayed an inverse correlation between high YAP1 and low NDR2 levels ([Figure 7](#fig7){ref-type="fig"}). Collectively, these findings suggest that NDR2 may serve a tumor-suppressive role in human colorectal cancer.

In summary, we establish mammalian NDR as bona fide kinases phosphorylating YAP1 on the key regulatory site S127 in vitro and in vivo. NDR kinases function as tumor suppressors in the intestinal epithelium by negatively regulating YAP1. In general, our data strongly suggest that the contribution of NDR kinases to YAP1 regulation should be accounted for in future YAP1-related studies and reconsidered in settings where the nature of the direct S127 kinase has remained elusive. Collectively, our findings provide significant new insights for a broad range of research efforts aimed at decoding and eventually manipulating YAP1-driven biology with the aim of improving cancer treatment and regenerative medicine.

Experimental Procedures {#sec4}
=======================

Animal Experiments {#sec4.1}
------------------

All animal experiments were carried out in compliance with animal welfare regulation and approved by the Swiss Cantonal Veterinary Office of Basel.

Colon Carcinogenesis Model {#sec4.2}
--------------------------

Adult mice (aged 10 weeks, body weight ≥20 g) of the indicated *Ndr* genotypes were injected intraperitoneally with 7.4 mg/kg body weight AOM (Sigma) on day 1. From day 14 to day 21, drinking water was supplemented with 2% DSS (MP Biomedicals). On day 64, mice were sacrificed and tissue samples were collected for analysis.

Human Colon Cancer Tissue Microarray {#sec4.3}
------------------------------------

A tissue microarray (TMA) of unselected, nonconsecutive human colorectal cancer (CRC) samples was described previously \[[@bib51]\]. In brief, formalin-fixed, paraffin-embedded tissue blocks of CRC resections were retrieved from the archives of the Institute of Pathology, University Hospital Basel, and the Institute of Clinical Pathology, Basel. A table with clinicopathological features of each sample is available upon request. Failure of analysis (\<10% of all cases) was related to TMA technology, including missing samples or fractions containing only a few tumor cells. The NDR2 and YAP IHC staining protocols were identical to those established for mouse samples (see the [Supplemental Experimental Procedures](#app2){ref-type="sec"}).

See the [Supplemental Experimental Procedures](#app2){ref-type="sec"} for detailed descriptions of kinase assays, tissue-culture experiments, plasmids, antibodies, and IHC.

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures, Figures S1--S4, and Tables S1--S3Document S2. Article plus Supplemental Information
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Supplemental Information includes Supplemental Experimental Procedures, four figures, and three tables and can be found with this article online at [http://dx.doi.org/10.1016/j.cub.2014.11.054](10.1016/j.cub.2014.11.054){#intref0010}.

![Mammalian NDR Kinases Restrain Proliferation and Hyperplastic Growth in the Intestinal Epithelium\
(A and B) Hyperplastic patches in the intestinal epithelium of *N1/2* cDKO (*Ndr1*^−/−^*Ndr2*^f/f^ Vil-Cre^+^) mice (A: small intestine; B: colon) visualized by H&E staining. Larger magnification of the hyperplastic areas and control regions are shown below. Scale bars represent 400 μm (upper panels) and 100 μm (lower panels).\
(C and D) Ki-67 IHC staining (brown) in *N1/2* cDKO and control mice (top) and corresponding quantification (bottom) (C: small intestine; D: colon). Numbers represent the average of a total of 200 crypts counted in five mice per genotype. Student's t test: ^∗^p1 = 3 × 10^−7^, ^∗^p2 = 4 × 10^−8^, ^∗^p3 = 9 × 10^−3^, ^∗^p4 = 3 × 10^−3^. Scale bars represent 100 μm.\
See also [Figure S1](#app2){ref-type="sec"}.](gr1){#fig1}

![NDR Kinases Protect against AOM/DSS-Induced Colon Carcinogenesis\
(A) AOM/DSS treatment protocol. Arrows indicate time points of tissue analysis in wild-type mice (see [Figure 3](#fig3){ref-type="fig"}). D, day.\
(B) Representative pair of *N1/2* cDKO and control colons post-AOM/DSS treatment after dissection at day 64.\
(C) H&E-stained sections of colon nodules in AOM/DSS-treated *N1/2* cDKO and control mice after dissection at day 64. Scale bars represent 500 μm (upper panels) and 100 μm (lower panels).\
(D) Quantification of colon nodule numbers in *N1/2* cDKO and control mice post-AOM/DSS treatment after dissection at day 64. Lines indicate the average tumor number in a given group. Student's t test: p1 = 9 × 10^−6^, p2 = 0.02, p3 = 8 × 10^−3^.\
See also [Figure S2](#app2){ref-type="sec"} and [Table S1](#app2){ref-type="sec"}.](gr2){#fig2}

![NDR2 Protein Is Progressively Lost during Colon Carcinogenesis\
Tissue architecture (H&E) and NDR2, β-catenin, and Ki-67 IHC staining of the colonic epithelium of wild-type C57BL6 mice after AOM/DSS. Serial sections were taken for the different stainings at each time point. Arrows indicate aberrant crypts. Scale bars represent 100 μm. Three mice were analyzed for each time point, as follows.\
(A) Prior to AOM injection.\
(B) D7: 1 week after AOM intraperitoneal injection.\
(C) D21: 1 week after completion of 2% DSS treatment.\
(D) D42: 3 weeks after completion of 2% DSS treatment.\
(E) D64: 6 weeks after completion of 2% DSS treatment and the end of the time course.](gr3){#fig3}

![Loss of NDR Causes YAP1 Upregulation in the Intestinal Epithelium\
(A) Western blot analysis of total colon lysates using the indicated antibodies.\
(B) Quantification of total YAP1 levels from (A) normalized to tubulin in different genotypes relative to WT. Each bar represents the western blot (WB) signal intensity of three different mice. Student's t test: p1 = 0.02, p2 = 0.03.\
(C) YAP1 IHC staining (brown) in the colon of *N1/2* cDKO and control mice (WT Vil-Cre). Bottom: YAP1 staining without counterstain. Scale bars represent 30 μm. See [Figure S3](#app2){ref-type="sec"}D for quantification.\
(D) PTEN IHC staining (brown) in the colon of *N1/2* cDKO and control mice. Scale bars represent 100 μm. See [Figure S3](#app2){ref-type="sec"}H for quantification.\
(E) *Bdnf* in situ hybridization (brown) in the colon of *N1/2* cDKO and control mice and quantification. Student's t test: p = 3 × 10^−4^. Scale bars represent 50 μm. See also [Figures S3](#app2){ref-type="sec"}I and S3J.\
(F) Quantification of colon nodule numbers in *N1/2* cDKO and *N1/2* cDKO mice with heterozygous deletion of *Yap1* post-AOM/DSS treatment after dissection at day 64. Lines indicate the average tumor number in a given group. Student's t test: p = 6.7 × 10^−6^.\
See also [Figures 2](#fig2){ref-type="fig"}D and [S3](#app2){ref-type="sec"}.](gr4){#fig4}

![NDR Kinases Phosphorylate hYAP1 on Ser127\
(A) Constitutively active NDR1 (glutathione S-transferase \[GST\]-NDR1-PIF) phosphorylates GST-YAP1 on serine 127. Kinase assays were carried out with the indicated proteins in the presence of radiolabeled ATP (^32^P). Kinase-dead (KD) NDR1 serves as negative control. Top: western blot with phospho-S127 YAP1 antibody; middle: autoradiography; bottom: Coomassie (loading control). See also [Table S2](#app2){ref-type="sec"}.\
(B) Endogenous protein levels of phospho-S127 YAP1, phospho-S381 YAP1, and total YAP1 in SW480 cells transiently overexpressing the indicated hemagglutinin (HA)-tagged NDR constructs. Phospho-S127 YAP1 levels (normalized to total YAP1 and vector control) are shown.\
(C) Endogenous protein levels of phospho-127 YAP1, phospho-381 YAP1, and total YAP1 in stable SW480 cell pools that overexpress untagged wild-type or kinase-dead NDR2 in a tetracycline-inducible manner. LATS1 levels remained stable. Phospho-S127 YAP1 levels (normalized to total YAP1 and vector control) are shown.](gr5){#fig5}

![NDR Regulates the Cellular Distribution and Transcriptional Activity of YAP1\
(A) Left: cellular distribution of endogenous YAP1 in SW480 cells overexpressing wild-type or kinase-dead Ndr2 in a tet-inducible manner (top: immunofluorescent \[IF\] staining for YAP1; bottom: merge of IF YAP1 and 4′,6-diamidino-2-phenylindole \[DAPI\]). Right: quantification of the nuclear/cytoplasmic YAP1 ratio per cell (n = 50 per condition). Student's t test: ^∗^p = 6 × 10^−6^. Scale bars represent 10 μm.\
(B) TEAD-luciferase reporter assay in SW480 cells transiently transfected with empty vector, WT, or KD Ndr2. Firefly luciferase activity was normalized to Renilla signal (n = 3). Student's t test: ^∗^p = 1 × 10^−7^.\
(C) Proliferation curves of SW480 cells expressing WT or KD Ndr2 in a tet-inducible manner.\
(D) Colony formation assay with the same cell lines as in (C). Colony numbers were scored 10 days after seeding (n = 3). Student's t test: ^∗^p = 9 × 10^−3^.\
See also [Figure S4](#app2){ref-type="sec"}.](gr6){#fig6}

![NDR2 and YAP1 Levels Are Inversely Correlated in Human Colon Cancer Samples\
(A) YAP1 (blue) and NDR2 (brown) IHC staining in human colon adenocarcinoma and adjacent normal colon crypts. Scale bars represent 50 μm.\
(B) Representative images of YAP1 and NDR2 IHC staining score in human colon cancer tissue microarrays (n = 400).\
(C) NDR2 expression in tissue microarray samples with high versus low YAP1 levels. Absolute sample numbers are provided in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.\
See also [Table S3](#app2){ref-type="sec"}.](gr7){#fig7}
